X4 Pharmaceuticals (XFOR) Misses Q4 EPS by 4c

X4 Pharmaceuticals (NASDAQ: XFOR) reported Q4 EPS of ($0.20), $0.04 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $1.43 million versus the consensus estimate of $990.71 thousand.

For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.

You May Also Be Interested In

• HSBC upgrades EU stocks, downgrades EM on increased volatility
• Weight Watchers and FlavCity launch summer protein product and program
• Supermicro launches Kubernetes edge AI appliances with Red Hat, Everpure